New and emerging biologics in the treatment of inflammatory bowel disease

quo vadis?

S. Danese, E. Angelucci

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Inflammatory bowel diseases (IBD) are pathological conditions characterized by chronic inflammation that is primarily the consequence of dysregulation of the immune response. Over the last decade, the advances in the pathophysiology of IBD have paved the way for the development of a number of biological agents that selectively target specific molecules and/or pathways involved in gut inflammation. Although numerous, so far, the only biological therapeutics that are approved for the treatment for IBD are monoclonal antibodies against tumor necrosis factor alpha. This paper systematically reviews the mechanismof-action, efficacy, short-term and, where available, long-term safety of biological agents that target molecules other than tumor necrosis factor alpha, in IBD.

Original languageEnglish
JournalGastroenterologie Clinique et Biologique
Volume33 Suppl 3
Publication statusPublished - Jun 2009

Fingerprint

Biological Products
Inflammatory Bowel Diseases
Biological Factors
Tumor Necrosis Factor-alpha
Inflammation
Monoclonal Antibodies
Safety
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

New and emerging biologics in the treatment of inflammatory bowel disease : quo vadis? / Danese, S.; Angelucci, E.

In: Gastroenterologie Clinique et Biologique, Vol. 33 Suppl 3, 06.2009.

Research output: Contribution to journalArticle

@article{f95d845366ec4a84b32d5306e6a3378c,
title = "New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis?",
abstract = "Inflammatory bowel diseases (IBD) are pathological conditions characterized by chronic inflammation that is primarily the consequence of dysregulation of the immune response. Over the last decade, the advances in the pathophysiology of IBD have paved the way for the development of a number of biological agents that selectively target specific molecules and/or pathways involved in gut inflammation. Although numerous, so far, the only biological therapeutics that are approved for the treatment for IBD are monoclonal antibodies against tumor necrosis factor alpha. This paper systematically reviews the mechanismof-action, efficacy, short-term and, where available, long-term safety of biological agents that target molecules other than tumor necrosis factor alpha, in IBD.",
author = "S. Danese and E. Angelucci",
year = "2009",
month = "6",
language = "English",
volume = "33 Suppl 3",
journal = "Clinics and Research in Hepatology and Gastroenterology",
issn = "2210-7401",
publisher = "Elsevier Masson",

}

TY - JOUR

T1 - New and emerging biologics in the treatment of inflammatory bowel disease

T2 - quo vadis?

AU - Danese, S.

AU - Angelucci, E.

PY - 2009/6

Y1 - 2009/6

N2 - Inflammatory bowel diseases (IBD) are pathological conditions characterized by chronic inflammation that is primarily the consequence of dysregulation of the immune response. Over the last decade, the advances in the pathophysiology of IBD have paved the way for the development of a number of biological agents that selectively target specific molecules and/or pathways involved in gut inflammation. Although numerous, so far, the only biological therapeutics that are approved for the treatment for IBD are monoclonal antibodies against tumor necrosis factor alpha. This paper systematically reviews the mechanismof-action, efficacy, short-term and, where available, long-term safety of biological agents that target molecules other than tumor necrosis factor alpha, in IBD.

AB - Inflammatory bowel diseases (IBD) are pathological conditions characterized by chronic inflammation that is primarily the consequence of dysregulation of the immune response. Over the last decade, the advances in the pathophysiology of IBD have paved the way for the development of a number of biological agents that selectively target specific molecules and/or pathways involved in gut inflammation. Although numerous, so far, the only biological therapeutics that are approved for the treatment for IBD are monoclonal antibodies against tumor necrosis factor alpha. This paper systematically reviews the mechanismof-action, efficacy, short-term and, where available, long-term safety of biological agents that target molecules other than tumor necrosis factor alpha, in IBD.

UR - http://www.scopus.com/inward/record.url?scp=79952112410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952112410&partnerID=8YFLogxK

M3 - Article

VL - 33 Suppl 3

JO - Clinics and Research in Hepatology and Gastroenterology

JF - Clinics and Research in Hepatology and Gastroenterology

SN - 2210-7401

ER -